Jubiliant Life Sciences got USFDA approval for selling its generic drugs in US market

Jan 6, 2015 13:00 IST

Bangalore-based drug firm Jubilant Biosys Ltd on 5 January 2014 received final approval of the US Food & Drug Administration (FDA) for its generic drugs Mycophenolate Mofetil and Rizatriptan. With this, Indian pharma major will now be able to sell these generic drugs in the American market.

Mycophenolate Mofetil, an immuno-suppressant, is a generic version of Roche's Cellcept whereas tablets of Rizatriptan, used for treatment of migraine, are generics of Merck's Maxalt tablets.

The strengths for which the approvals were given by the USFDA include
• Mycophenolate Mofetil – in strengths of 250 mg capsules and 500 mg tablets
• Rizatriptan tablets - in strengths of 5 mg and 10 mg

Mycophenolate Mofetil capsules and tablets are manufactured by the company's US arm Jubilant Cadista Pharmaceuticals Inc and Rizatriptan tablets are made at Jubilant Generics Ltd, Jubilant Life Sciences.


Is this article important for exams ? Yes10 People Agreed

Register to get FREE updates

    All Fields Mandatory
  • (Ex:9123456789)
  • Please Select Your Interest
  • Please specify

  • ajax-loader
  • A verifcation code has been sent to
    your mobile number

    Please enter the verification code below

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK